|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
1995
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:N07XX02
|
|
gptkbp:bioavailability
|
60%
|
|
gptkbp:brand
|
gptkb:Exservan
gptkb:Rilutek
gptkb:Teglutik
|
|
gptkbp:CASNumber
|
gptkb:1744-22-5
|
|
gptkbp:category
|
glutamate antagonist
neuroprotective agent
orphan drug
sodium channel blocker
|
|
gptkbp:contraindication
|
severe liver impairment
|
|
gptkbp:discoveredBy
|
gptkb:Rhône-Poulenc_Rorer
|
|
gptkbp:eliminationHalfLife
|
12 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:first_approved_in
|
gptkb:France
|
|
gptkbp:hasMolecularFormula
|
gptkb:C8H5F3N2OS
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
riluzole
|
|
gptkbp:interactsWith
|
gptkb:theophylline
gptkb:omeprazole
caffeine
CYP1A2 inhibitors
|
|
gptkbp:IUPACName
|
6-(trifluoromethoxy)benzothiazol-2-amine
|
|
gptkbp:KEGGID
|
gptkb:D08402
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
glutamate release inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
234.20 g/mol
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:proteinBinding
|
96%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1428
gptkb:DB00740
5070
4895
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
liver dysfunction
weakness
|
|
gptkbp:synonym
|
2-amino-6-(trifluoromethoxy)benzothiazole
|
|
gptkbp:UNII
|
7LJ087RS6F
|
|
gptkbp:usedFor
|
amyotrophic lateral sclerosis
|
|
gptkbp:bfsParent
|
gptkb:Amyotrophic_lateral_sclerosis
|
|
gptkbp:bfsLayer
|
4
|